General health maintenance in IBD

Inflammatory Bowel Diseases

Volumn 15, Issue 9, 2009, Pages 1399-1409

  Moscandrew, Maria ^a   Mahadevan, Uma ^b   Kane, Sunanda ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gastroenterologist; General health maintenance; Inflammatory bowel disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CHICKENPOX VACCINE; CYCLOSPORIN A; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLIXIMAB; INFLUENZA VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PNEUMOCOCCUS VACCINE; PREDNISONE; THIAZIDE DIURETIC AGENT; VITAMIN D; WART VIRUS VACCINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAL DYSPLASIA; ANUS DISEASE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AWARENESS; BLOOD PRESSURE MONITORING; BONE DENSITY; BREAST CANCER; CANCER SCREENING; COLONOSCOPY; CROHN DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENTERITIS; FRAGILITY FRACTURE; GASTROENTEROLOGY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LIFE CYCLE; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; LOW DRUG DOSE; OSTEOPOROSIS; POLYMYOSITIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSTATE CANCER; PSORIASIS; REVIEW; REYE SYNDROME; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SARCOIDOSIS; SEDIMENTATION RATE; SENSITIVITY AND SPECIFICITY; SKIN CANCER; SMOKING CESSATION; SQUAMOUS CELL CARCINOMA; TREATMENT CONTRAINDICATION; TUBERCULIN TEST; UTERINE CERVIX DYSPLASIA; VACCINATION; HEALTH BEHAVIOR;

HEALTH BEHAVIOR; HUMANS; INFLAMMATORY BOWEL DISEASES; VACCINATION;

EID: 70449717232     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20944     Document Type: Review

References (94)

1. Selby L, Kane S, Wilson J. Receipt of preventive health services by IBD patients is significantly lower than by primary care patients. Inflamm Bowel Dis. 2008;14:253-258. (Pubitemid 351288048)
2. Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:677-692. (Pubitemid 39276481)
3. Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101:1834-1840. (Pubitemid 44166594)
4. ACIP. Recommended adult immunization schedule: United States, 2009. Ann Intern Med. 2009;150:40-44.
5. Nielsen HJ, Mortensen T, Holten-Andersen M, et al. Increased levels of specific leukocyte- and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease. Scand J Gastroenterol. 2001;36:265-269. (Pubitemid 32234575)
6. Lu Y, Jacobson DL, Ashworth LA, et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol. 2009;104:444-453.
7. Mamula P, Markowitz JE, Piccoli DA, et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:851-856. (Pubitemid 47031059)
8. Melmed GY, Frenck, R. Barolet-Garcia, et al. TNF blockers and immunomodulators impair antibody response to pneumoccocal polysaccharide vaccine (Ppv) in patients with inflammatory bowel disease. Gastroenterology. 2008;134:A-68, Abstract 495.
9. Brezinschek HP, Hofstaetter T, Leeb BF, et al. Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexate. Curr Opin Rheumatol. 2008;20:295-299.
10. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol. 2007;34:272-279. (Pubitemid 46255742)
11. Duchet-Niedziolka P, Coutsinos Z, Hanslik T, Launay O. Anti-TNFalpha therapy and vaccination of adults. Joint Bone Spine. 2007;74:563-565.
12. Fields SW, Baiocco PJ, Korelitz BI. Influenza vaccinations: should they really be encouraged for IBD patients being treated with immunosuppressives? Inflamm Bowel Dis. 2009;15:649-651.
13. CDC. Prevention of herpes zoster. MMWR. 2008;57:1-30.
14. CDC. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha-California, 2002-2003. MMWR. 2004;53:683-686.
15. Society AT. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000;161:S221-2247.
16. Bolyard EA, Tablan OC, Williams WW, et al. Guideline for infection control in healthcare personnel, 1998. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1998;19:407-463.
17. Mow WS, Abreu-Martin MT, Papadakis KA, et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol. 2004;2:309-313.
18. Fuchs I, Avnon L, Freud T, Abu-Shakra M. Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors. Clin Rheumatol. 2009;28:167-172.
19. Kunst H. Diagnosis of latent tuberculosis infection: the potential role of new technologies. Respir Med. 2006;100:2098-2106. (Pubitemid 44724568)
20. Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:19-30. (Pubitemid 350212629)
21. Perlmutter A, Mittal A, Menter A. Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol. 2009;160:8-15.
22. Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2008;6:1218-1224.
23. Romanato G, Scarpa M, Angriman I, et al. Plasma lipids and inflammation in active inflammatory bowel diseases. Aliment Pharmacol Ther. 2009;29:298-307.
24. Gisbert JP, Gomollon F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol. 2008;103:1299-1307. (Pubitemid 351678000)
25. Gilman J, Shanahan F, Cashman KD. Determinants of vitamin D status in adult Crohn's disease patients, with particular emphasis on supplemental vitamin D use. Eur J Clin Nutr. 2006;60:889-896. (Pubitemid 43997702)
26. Van Staa TP, Travis S, Leufkens HG, et al. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology. 2004;126:1733-1739. (Pubitemid 38736338)
27. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-987. (Pubitemid 43374543)
28. Itzkowitz SH, Present DH. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:314-321.
29. van der Heide F, Dijkstra A, Weersma RK, et al. Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2009 (in press).
30. Johnson GJ, Cosnes J, Mansfield JC. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther. 2005;21:921-931. (Pubitemid 40529727)
31. Kane S, Altschuler EL, Kast RE. Crohn's disease remission on bupropion. Gastroenterology. 2003;125:1290.
32. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94:646-650. (Pubitemid 23166713)
33. Marshall D, Johnell O and Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254-1259. (Pubitemid 26147662)
34. Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med. 2000;133:795-799.
35. Loftus EV, Crowson CS, Sandborn WJ et al. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology. 2002;123:468-475.
36. Kanis JA, Melton LJ, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137-1141.
37. Bone density measurement - a systematic review. A report from SBU, the Swedish Council on Technology Assessment in Health Care. J Intern Med Suppl. 1997;739:1-60.
38. Nguyen T, Sambrook P, Kelly P, et al. Prediction of osteoporotic fractures by postural instability and bone density. BMJ. 1993;307:1111-1115.
39. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:795-841.
40. Bernstein CN (ed.). Guidelines for osteoporosis and inflammatory bowel disease. A guide to diagnosis and management for the gastroenterologist (monograph). Bethesda, MD: American College of Gastroenterology; 2003.
41. Reid IR, Ames RW, Evans MC, et al. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med. 1995;98:331-335.
42. Raisz LG. Clinical practice. Screening for osteoporosis. N Engl J Med. 2005;353:164-171.
43. Schoon EJ, Blok BM, Geerling BJ, et al. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology. 2000;119:1203-1208.
44. Smak Gregoor PJ, de Sevaux RG, Ligtenberg G, et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol. 2002;13:1365-1373. (Pubitemid 34441418)
45. Hilbrands LB, Hoitsma AJ, Koene KA. Randomized, prospective trial of cyclosporine monotherapy versus azathioprine-prednisone from three months after renal transplantation. Transplantation. 1996;61:1038-1046.
46. Hollander AA, Hene RG, Hermans J, et al. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. J Am Soc Nephrol. 1997;8:294-301. (Pubitemid 127455885)
47. He J, Whelton PK, Appel LJ, et al. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension. 2000;35:544-549. (Pubitemid 30108146)
48. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:3-10.
49. Vollmer WM, Sacks FM, Ard J, et al. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med. 2001;135:1019-1028. (Pubitemid 33151023)
50. Chobanian AV, Hill M. National Heart, Lung, and Blood Institute Workshop on Sodium and Blood Pressure: a critical review of current scientific evidence. Hypertension. 2000;35:858-863. (Pubitemid 30303940)
51. Kelley GA, Kelley KS. Progressive resistance exercise and resting blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2000;35:838-843.
52. Whelton SP, Chin A, Xin X, et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2002;136:493-503. (Pubitemid 34252283)
53. Xin X, He J, Frontoni MG, et al. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2001;38:1112-1117. (Pubitemid 34252815)
54. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002;4:393-404.
55. Bernklev T, Jahnsen J, Lygren I, et al. Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis. 2005;11:909-918. (Pubitemid 41428850)
56. Janke KH, Klump B, Gregor M, et al. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:272-286. (Pubitemid 40439682)
57. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology. 1994;106:287-296.
58. Turnbull GK, Vallis TM. Quality of life in inflammatory bowel disease: the interaction of disease activity with psychosocial function. Am J Gastroenterol. 1995;90:1450-1454.
59. Walker EA, Gelfand MD, Gelfand AN, et al. The relationship of current psychiatric disorder to functional disability and distress in patients with inflammatory bowel disease. Gen Hosp Psychiatry. 1996;18:220-229. (Pubitemid 26251507)
60. Nigro G, Angelini G, Grosso SB, et al. Psychiatric predictors of noncompliance in inflammatory bowel disease: psychiatry and compliance. J Clin Gastroenterol. 2001;32:66-68. (Pubitemid 32038115)
61. de Boer AG, Sprangers MA, Bartelsman JF, et al. Predictors of health care utilization in patients with inflammatory bowel disease: a longitudinal study. Eur J Gastroenterol Hepatol. 1998;10:783-789.
62. Fuller-Thomson E, Sulman J. Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys. Inflamm Bowel Dis. 2006;12:697-707. (Pubitemid 44253753)
63. Walker JR, Ediger JP, Graff LA, et al. The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am J Gastroenterol. 2008;103:1989-1997.
64. Felekis T, Katsanos K, Kitsanou M, et al. Spectrum and frequency of ophthalmologic manifestations in patients with inflammatory bowel disease: a prospective single-center study. Inflamm Bowel Dis. 2009;15:29-34.
65. Saslow D, Runowicz CD, Soloman D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52:342-362. (Pubitemid 35446606)
66. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103:631-636.
67. Bhatia J, Bratcher J, Korelitz B, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol. 2006;12:6167-6171. (Pubitemid 44688166)
68. Bjorge T, Engeland A, Luostarinen T, et al. Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. Br J Cancer. 2002;87:61-64. (Pubitemid 34888604)
69. Palefsky JM, Holly Ea, Gonzales J, et al. Detection of human papillomavirus DNA in anal intraepithelial neoplasia and anal cancer. Cancer Res. 1991;51:1014-1019.
70. Zaki SR, Judd R, Coffield LM, et al. Human papillomavirus infection and anal carcinoma. Retrospective analysis by in situ hybridization and the polymerase chain reaction. Am J Pathol. 1992;140:1345-1355.
71. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
72. Johnson LG, Madeleine MM, Newcomer LM, et al. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer. 2004;101:281-288.
73. Chiao EY, Krown SE, Stier EA, et al. A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J Acquir Immune Defic Syndr. 2005;40:451-455.
74. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
75. Riegler G, Caserta L, Castiglione F, et al. Increased risk of breast cancer in first-degree relatives of Crohn's disease patients. An IG-IBD study. Dig Liver Dis. 2006;38:18-23.
76. Sogaard KK, Cronin-Fenton DP, Pedersen L, et al. Survival in Danish patients with breast cancer and inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis. 2008;14:519-525. (Pubitemid 351571832)
77. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2008: a review of current American Cancer Society guidelines and cancer screening issues. CA Cancer J Clin. 2008;58:161-179.
78. National Cancer Institute. Cancer Stat Fact Sheets. June 3, 2008.
79. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:185-191.
80. Webb MC, Compton F, Andrews PA, et al. Skin tumours posttransplantation: a retrospective analysis of 28 years' experience at a single centre. Transplant Proc. 1997;29:828-830. (Pubitemid 27125980)
81. Winkelhorst JT, Brokelman WJ, Tiggeler RG, et al. Incidence and clinical course of de-novo malignancies in renal allograft recipients. Eur J Surg Oncol. 2001;27:409-413. (Pubitemid 32624545)
82. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40:177-186.
83. Hartevelt MM, Bavinck JN, Kootte AM, et al. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation. 1990;49:506-509.
84. Lindelof B, Sigurgeirsson B, Gabel H, et al. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol. 2000;143:513-519. (Pubitemid 30743335)
85. Bouwes Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A followup study. Transplantation. 1996;61:715-721.
86. Glover MT, Deeks JJ, Raftery MJ, et al. Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet. 1997;349:398.
87. Gaya SB, Rees AJ, Lechler RI, et al. Malignant disease in patients with long-term renal transplants. Transplantation. 1995;59:1705-1709.
88. Birkeland SA, Storm HH, Lamm LU, et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer. 1995;60:183-189.
89. Penn I. Malignant melanoma in organ allograft recipients. Transplantation. 1996;61:274-278. (Pubitemid 26044543)
90. Moloney FJ, Comber H, O'Lorcain P, et al. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol. 2006;154:498-504. (Pubitemid 43382659)
91. Buchbinder R, Barber M, Heuzenroeder L, et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 2008;59:794-799.
92. Bavinck JN, De Boer A, Vermeer BJ, et al. Sunlight, keratotic skin lesions and skin cancer in renal transplant recipients. Br J Dermatol. 1993;129:242-249. (Pubitemid 23283993)
93. Ekbom A, Helmick C, Zack M, et al. Extracolonic malignancies in inflammatory bowel disease. Cancer. 1991;67:2015-2019.
94. Jess T, Winther KV, Munkholm P, et al. Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther. 2004;19:287-293.